Skip to content

How to Use Melanotan II: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

MT-II is administered via subcutaneous injection into abdominal fat, the thigh, or the deltoid region. It is supplied as a lyophilized powder requiring reconstitution before use.

Injection Procedure:

  1. Clean the injection site with an alcohol swab
  2. Pinch a skin fold to isolate subcutaneous tissue
  3. Insert needle at a 45–90 degree angle
  4. Inject solution slowly
  5. Withdraw the needle and apply gentle pressure

Insulin syringes (29–31 gauge, 0.5–1 mL) are commonly used for administration. Rotating injection sites is recommended to prevent lipodystrophy.

Nasal spray formulations exist but have significantly lower and less predictable bioavailability than subcutaneous injection, and are generally not favored by experienced users.

Reconstitution, Storage & Prep

MT-II is supplied as sterile lyophilized powder, typically in 10 mg vials.

Reconstitution Process:

  1. Allow vial to reach room temperature
  2. Using a sterile syringe, draw bacteriostatic water (preferred) or sterile water
  3. Inject water slowly down the inside wall of the vial, do not spray directly onto powder
  4. Gently swirl (do not shake) until fully dissolved
  5. The solution should be clear and colorless; do not use if cloudy or particulate matter is visible

Common Reconstitution Ratio:

  • 10 mL bacteriostatic water added to a 10 mg vial yields 1 mg/mL (100 mcg per 0.1 mL / 10 units on an insulin syringe)

Storage Guidelines:

  • Unreconstituted powder: Refrigerate (2–8°C) or freeze; stable for 12+ months
  • Reconstituted solution: Refrigerate at 2–8°C and use within 4–6 weeks
  • Protect from light; avoid repeated freeze-thaw cycles
  • Do not use if solution appears cloudy or contains visible particles

Frequently Asked Questions

Most users notice enhanced tanning within 2–3 weeks when combining MT-II with moderate UV exposure. Initial darkening may be subtle, with pronounced results developing over 4–6 weeks of consistent use.

While MT-II stimulates melanin production, UV exposure significantly enhances and accelerates visible results. Some report mild darkening without UV, but optimal results require at least minimal sun or sunbed exposure.

Yes, MT-II has been colloquially called the "Barbie drug" in media reports, referencing its use for a tanned appearance. This originated in tabloid coverage and does not reflect any official designation.

Starting with lower doses (0.1–0.25 mg), administering before bedtime, and ensuring adequate hydration reduce nausea. Antihistamines taken 30 minutes before injection may help. Nausea typically diminishes after the first week.

Yes, existing moles and freckles commonly darken with MT-II use. This is expected given the peptide's mechanism but warrants monitoring. Any moles showing irregular changes in shape, border, or color should be evaluated by a dermatologist.

Yes, MT-II is used by both men and women for tanning purposes. Women may experience increased libido as a side effect. Pregnant or breastfeeding women should avoid MT-II due to lack of safety data.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-84.
  2. Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. 1998;160(2):389-93.
  3. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30.
  4. Fan W, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-8.
  5. Brennan R, et al. Melanotan II: a review of the evidence for efficacy and safety. Dermatology Online Journal. 2019.
  6. U.S. Food and Drug Administration. Tainted Sexual Enhancement Products. FDA Consumer Updates.
  7. World Anti-Doping Agency. The 2024 Prohibited List. WADA.
  8. Hruby VJ, et al. Cyclic lactam alpha-melanotropin analogues with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. Journal of Medicinal Chemistry. 1995;38(18):3454-61.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”